CDK4 and medulloblastoma: They also demonstrated that CDK4/CDK6 inhibition delays the acquisition of BET inhibitor resistance, and the combination of JQ1 with LEE01 (a CDK4/6 inhibitor) improved survival, compared to monotherapy in flank and orthotopic xenograft models of MYC-driven medulloblastoma.